Action XBRANE XBRANE BIOPHARMA AB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Xbrane Biopharma AB

Actions

XBRANE

SE0007789409

Temps Différé Nasdaq Stockholm
Autres places de cotation
 12:51:37 16/07/2024 		Varia. 5j. Varia. 1 janv.
0,2415 SEK +5,23 % Graphique intraday de Xbrane Biopharma AB +14,18 % -97,58 %
22/05 Xbrane réussit la mise à l'échelle de Xdivane - candidat biosimilaire à Opdivo® ? CI
16/05 Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Xbrane provides update on its development portfolio
Xbrane Provides update on timing of re-submission of BLA for ranibizumab biosimilar candidate
Xbrane Biopharma : successfully scales up Xdivane™ biosimilar candidate to Opdivo® and run an active partnering process
Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo® - and run an active partnering process
Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®?
Xbrane Biopharma Q1 2024 - Approaching an eventful second half of the year
Xbrane Biopharma releases Interim Report for January-March 2024
Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Xbrane Biopharma : Invitation to presentation of Xbrane Biopharma's interim report January - March 2024 on May 16, 2024
Invitation to presentation of Xbrane Biopharma’s interim report January – March 2024 on May 16, 2024
Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar
Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US
Announcement from Xbrane Biopharma's annual general meeting
Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director
Xbrane provides regulatory update on FDA review of its ranibizumab biosimilar candidate
Notice of annual general meeting in Xbrane Biopharma AB
Change of number of shares and votes in Xbrane
XBRANE BIOPHARMA RELEASES ANNUAL AND SUSTAINABILITY REPORT FOR 2023
Xbrane resolves on a directed issue of shares to guarantors in connection with the completed rights issue
Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action XBRANE
  4. Actualités Xbrane Biopharma AB
  5. Autres langues